The EU strategy in Horizon2020 to fight poverty related diseases

Transcription

1 Meeting on EDCTP2 French Ministry of Education, Science and Innovation, Paris 30 June 2017 The EU strategy in Horizon2020 to fight poverty related diseases Line Matthiessen Acting Director Health Directorate DG Research & Innovation European Commission Brussels, Belgium

2 The involvement of the EU in research and innovation for PRND The EU is the world's 2 nd largest public funder of research on povertyrelated and neglected infectious diseases Of the top three funders, only the EU significantly increased funding (+20%) in 2015, due to its expanded contributions under EDCTP2

3 Horizon 2020 ( ): The EU funding instrument for PRND Societal Challenge 1 (SC1) Health, Demographic change and Well being EUR: 7.4 billion

4 The fight against PRNDs: one challenge, many instruments Public-private partnership with big pharma Collaborative projects Public-public partnerships with EU Member States & beyond GTBVP Grants for small businesses Blue sky research Loans for small and big R&I companies Knowledge triangle: Higher education, business, R&I

5 PRND research portfolio in H2020 (MSCA ERC- SC1) EUR 269 million* ( ) HIV/AIDS 80 million Tuberculosis 49 million Malaria 40 million NIDs(including ebola and zika) 100 million Main areas covered Basic research - host-pathogen interactions, genomics, mode of transmission, immune modulators Translational research (including early clinical trials) - developement or optimisation of novel diagnostics tools, vaccines, treatment and curative options, Epidemiological research networks for outbreaks prepareness, infrastructures for data and samples sharing Personalised medicine - development of tools for mhealth * Not including EDCTP2, IMI2

6 Main funding instruments under Societal Challenges Health for PRND research Collaborative research and Horizon challenge prizes European and Developing Countries Clinical Trials Partnership (EDCTP2) Innovative Medicines Initiative Public Private Partnership between the European Union and the pharmaceutical industry association EFPIA InnovFin ID loans

7 EC funding instruments for feeding the pipeline PUSH Resources required Risk level PULL Discovery, PoC Preclinic Clinical Phases 1-3 Upscaling Manufacturing Uptake Delivery Collaborative research EDCTP InnovFin ID Horizon Prize IMI

8 Collaborative research actions for innovative solutions for PRND Implemented by DG RTD With option of emergency procedure w/o call for proposal Between countries: Multinational consortia: with at least 3 partners from 28 EU Member States (MS) or Associated Countries (AC) Researchers from any country in the world can participate. Low and middle income countries are eligible for EU funding Between different types of organizations public & private sector: universities, research centres, patients organisations, civil society, industry, SMEs, etc. Between disciplines multidisciplinary, translational research

9 SC1: Collaborative platforms for vaccine development TB, HIV, malaria TBVAC m Advancing novel an promising TB vaccine candidates from discovery to preclinical and early clinical development EMI-TB - 8m Eliciting mucosal immunity in tuberculosis EHVA m Develop Multidisciplinary Vaccine Platform for prophylactic and therapeutic HIV Vaccines candidates and assays for identification of immune correlates EAVI Develop vaccine platform for novel preventive/therapeutic vaccine candidates from discovery to early clinical testing OptiMalVax - 20m Optimizing a deployable high efficacy malaria vaccine MultiViVax - 5 m Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria Feeding the pipeline for EDCTP2

10 A New Financial Instrument for Infectious Diseases R&D Jointly developed by the European Commission and European Investment Bank Provides loans between EUR 7.5m and EUR 75m to innovative players active in developing vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases No calls demand-driven Launched 15 June 2015 in Riga during 'The First Innovative Enterprise Week' *

11 InnovFin loans signed so far CAVIDI (Swedish SME) 10 million loan Allows Cavidi to develop an automated, high-throughput version of a low-cost HIV viral load testing devise validated under a FP7- project MOBIDIAG (Finnish SME) 15 million loan Allows to finalise and scale up manufacturing, validation and commercialisation of a diagnostic tool for Infectious Diseases TRANSGENE (French SME) 20 million loan Supports the development of innovative treatments for hepatitis B, tuberculosis as well as human papillomavirus-induced cancer STAT-Diagnostica & Innovation, (Spanish SME) 20 million loan Supports the development of a new molecular diagnostics device capable of identifying a wide range of infectious pathogens, such as meningitis, respiratory or gastro-intestinal infections. BiondVax Pharmaceuticals Ltd. (Israeli SME) 20 million loan Supports the development of a Universal Flu Vaccine candidate

12 Horizon Prizes Horizon Prizes are 'challenge' prizes offering a cash reward to whoever can most effectively meet a defined challenge The aim is to stimulate innovation and come up with solutions to problems that matter to European citizens A technological or societal challenge is defined without defining the path how to reach it The contestants are free to come up with the most promising and effective solution within a given deadline The prize is awarded for the best delivered breakthrough solution in a competitive contest

13 Birth Day Prize Approximately 300,000 women died from preventable causes related to pregnancy and childbirth in 2013 Maternal and perinatal conditions are the seventh contributors to the global burden of disease Horizon Prize on reducing maternal and new-born morbidity and mortality the Birth Day Prize The prize calls for a novel solution to improve the outcome of facility-based deliveries (of a clinical, technological or managerial nature, or a combination of these) Developed by European Commission, Bill & Melinda Gates Foundation, and MSD for Mothers programme of Merck Sharp & Dohme Corporation More details: deadline 6 th September From the EC: 1 million

14 Multi- funders initiatives on infectious diseases GTBVP

15 Global Research Collaboration for Infectious Diseases Preparedness - Objectives Facilitate exchange of information in outbreak situations Establish a response plan and a strategic agenda for a coordinated and rapid research response Address scientific, legal, ethical and financial challenges to a rapid response Connect infectious disease research networks Supports public health decision-making Is NOT a new funding organisation

16 Members NORWAY MEXICO CANADA USA UNITED KINGDOM FRANCE SPAIN GERMANY EUROPEAN COMMISSION WHO ITALY EGYPT INDIA SOUTH KOREA THAILAND JAPAN BRAZIL AFRICA ARGENTINA SOUTH AFRICA AUSTRALIA Observer Status: World Health Organization (WHO)

17 Global TB Vaccine Partnership (GTBVP) Global collaboration of funding organisations, industry, PPPs, national governments and public and private organisations active in development of TB vaccine R&D To track and collate global TB vaccine strategies, intervention target product profiles, preferred product characteristics, and candidates in discovery, pre-clinical and clinical development Aim to develop and regularly update stage gating criteria suggested for moving TB vaccine candidates through pre-clinical and clinical stages of product development

18 #EUAMRaction

19 ONE HEALTH

20 MAKING THE EU A BEST PRACTICE REGION ON AMR Better evidence and awareness Better coordination and implementation of EU rules Better prevention and control Better addressing the role of the environment A stronger partnership against AMR and better availability of antimicrobials BOOSTING RESEARCH, DEVELOPMENT AND INNOVATION ON AMR New economic models & incentives Better detection and control measures New antimicrobials, rapid diagnostic tests, vaccines & alternative therapies AMR in the environment SHAPING THE GLOBAL AGENDA ON AMR Stronger EU global presence, partnering Stronger bilateral partnership for stronger cooperation Cooperating with developing countries Developing a global research agenda

21 Pillar 2 Boosting research, development and innovation The Commission will: Improve knowledge on detection, effective infection control and surveillance Develop new therapeutics and alternatives Develop new preventive vaccines Develop novel diagnostics Develop new economic models and incentives Close knowledge gaps on AMR in the environment and on how to prevent transmission Special attention to WHO's priority list, TB, HIV, malaria and neglected infectious diseases

22 DEVELOPING A GLOBAL RESEARCH AGENDA The Commission will: Improve global coordination of research activities by promoting dialogue and collaboration between international research initiatives Support the establishment of a virtual research institute under JPIAMR Continue collaborative research with sub-saharan Africa in the context of EDCTP, in particular in relation to TB, HIV, malaria and NID Foster international research collaboration on AMR in the animal health sector in the STAR-IDAZ International Research Consortium Please find here the link to the EC press release for the AMR Action Plan:

23 THANK YOU